公开(公告)号：US20220387516A1

公开(公告)日：2022-12-08

申请号：US17755275

申请日：2020-11-02

申请人： FIGENE, LLC

发明人： Pete O'HEERON ,  Thomas ICHIM

IPC分类号： A61K35/33 ,  A61K35/17 ,  A61K35/545 ,  A61K35/50 ,  A61K39/00 ,  A61P35/00

摘要： Described are means of generating immunological compositions that are universally applicable for induction of immunity to neoplasia regardless of histological origin of tissue. Certain methods concern fibroblasts that are manipulated or dedifferentiated in a manner to induce expression of tumor associated antigens including cancer testis antigens. These cells are used as a source of antigenic stimuli for creation of a cellular vaccine, and/or an exosome vaccine, and/or a lysate-based vaccine.

公开(公告)号：US20220339102A1

公开(公告)日：2022-10-27

申请号：US17640997

申请日：2020-09-04

申请人： MDIMUNE INC. ,  INHA-INDUSTRY PARTNERSHIP INSTITUTE

发明人： Shin Gyu Bae ,  Seung Wook OH ,  Se Hee Kim ,  Sung Hoon Han ,  Jeong Seok Choi ,  Jeong Mi Kim

IPC分类号： A61K9/127 ,  A61K35/28 ,  A61K35/50 ,  A61K35/545 ,  A61K35/42 ,  A61K35/34 ,  A61K35/19 ,  A61K9/00 ,  A61K9/48 ,  A61K9/20 ,  A61P1/02

摘要： The present invention relates to a salivary gland therapeutic agent using the effects of a cell-derived vesicle of enhancing the proliferation capacity of salivary gland cells, promoting an amylase activity, and enhancing transepithelial resistance. A pharmaceutical composition comprising the cell-derived vesicle according to the present invention has the effects of enhancing the proliferation capacity of salivary gland cells damaged by radiation, promoting amylase activity, increasing transepithelial resistance, enhancing the expression of Aquaporin 5, and increasing the amount of saliva secretion. Therefore, the pharmaceutical composition comprising the cell-derived vesicle of the present invention can be used for preventing and treating salivary gland diseases, and thus can be widely used in the pharmaceutical industry and health functional food field.

公开(公告)号：US20220305061A1

公开(公告)日：2022-09-29

申请号：US17842156

申请日：2022-06-16

申请人： AXOLOTL BIOLOGIX, INC.

发明人： Robert S. Kellar ,  Robert B. Diller ,  Robert G. Audet ,  Eric T. Lee ,  Andrew T. Vo

IPC分类号： A61K35/50 ,  C12N5/073 ,  A61K38/17 ,  A61P19/04 ,  A61P17/02 ,  A61K38/18 ,  A61K38/19 ,  A61K38/45 ,  A61K38/48 ,  A61P19/02

摘要： A method for making an acellular human amnion-derived composition configured for therapeutic use is disclosed and generally includes the steps: obtaining amniotic membrane tissue; testing the amniotic membrane tissue for pathogens; washing the amniotic membrane tissue; manually removing blood-containing chorion tissue from the amniotic membrane tissue decellularizing the amniotic membrane tissue with xeno-free enzymes; collecting amniotic cells from the decellularized amniotic membrane tissue; seeding the amniotic cells for culture into xeno-free media formulated for mesenchymal stem cells; growing the amniotic cells to a specified confluency; collecting conditioned media; and freezing the collected conditioned media; wherein the method further includes irradiating the conditioned media.

公开(公告)号：US11446334B2

公开(公告)日：2022-09-20

申请号：US17646539

申请日：2021-12-30

申请人： Amniotics AB

发明人： Jan Talts ,  Niels-Bjarne Woods ,  Kare Engkilde ,  Marcus Larsson

IPC分类号： A61K35/50 ,  A61K35/28 ,  A61P11/00 ,  C12N5/0775

摘要： Methods for purifying, culturing and selecting mesenchymal stem cell (MSC) subpopulations with neonatal quality and adult tissue specificity are for in production of advanced therapeutic medicinal products. In certain examples, term amniotic fluid derived cells having characteristics of lung cells can be isolated. In some the term amniotic fluid derived cells having characteristics of lung cells can be used in the treatment of acute and chronic respiratory diseases.

公开(公告)号：US20220218522A1

公开(公告)日：2022-07-14

申请号：US17657757

申请日：2022-04-03

申请人： Cetel Scientific LLC

发明人： Celso Tello

IPC分类号： A61F9/00 ,  A61K35/50

摘要： A biodegradable multi-purpose lens-shaped patch useful for healing and treatment of ocular conditions is disclosed. The patch is formed from a biodegradable carrier such as collagen from a mammalian source or a poly (DL-lactide co-glycolide) copolymer carrier. The carrier supports an amniotic extract and/or placental extract active ingredient. The lens-shaped patch may be shaped in the form of a conventional contact lens and it is applied to a corneal surface to enhance healing thereof. After a period of time ranging from one to thirty days, the patch degrades and completely dissolves and need not be removed. The degradation time can be adjusted by the use of crosslinking agents such as riboflavin.

公开(公告)号：US11382859B1

公开(公告)日：2022-07-12

申请号：US16787186

申请日：2020-02-11

申请人： BRAHM HOLDINGS, LLC

发明人： Timothy R. Brahm

IPC分类号： A61K8/98 ,  A61K35/51 ,  A61K35/50 ,  A61Q19/08 ,  A61Q19/00 ,  A61K35/48

摘要： A cosmetic composition for the repair and remodeling of the human skin is provided. The cosmetic composition includes a therapeutically effective amount of human birth tissue material and a suitable carrier composition. Methods of treating human skin with the cosmetic composition, methods of reducing the appearance of a skin condition arising from aging and a corresponding kit are also provided.

公开(公告)号：US20220211754A1

公开(公告)日：2022-07-07

申请号：US17607850

申请日：2020-04-29

申请人： PAEAN BIOTECHNOLOGY INC.

发明人： Kyuboem HAN ,  Chun-Hyung KIM ,  Shin-Hye YU ,  Seo-Eun LEE ,  Sang-Min LIM ,  Hahnsun JUNG ,  Kwangmin NA ,  Yoon Mi HAN ,  Jun Young SON ,  Eun Young LEE ,  Jeong Yeon KIM ,  Yeong Wook SONG ,  Jin Chul PAENG ,  Yun Sang LEE ,  Do Won HWANG

IPC分类号： A61K35/12 ,  A61K35/30 ,  A61K35/17 ,  A61K35/33 ,  A61K35/19 ,  A61K35/35 ,  A61K35/28 ,  A61K35/34 ,  A61K35/50 ,  A61K35/52 ,  A61K35/54 ,  A61K35/545

摘要： The present invention relates to a pharmaceutical composition for preventing or treating myositis. More particularly, the present invention relates to a pharmaceutical composition for preventing or treating myositis, comprising mitochondria as an active ingredient. When the pharmaceutical composition of the present invention comprising exogenous mitochondria as an active ingredient is administered to a subject suffering from myositis, inflammatory cells infiltrated into the muscle cells of the subject can be reduced. In addition, the pharmaceutical composition of the present invention effectively inhibits the expression of IL-1β, TNF-α, and IL-6, inflammatory cytokines. Therefore, the pharmaceutical composition according to the present invention can be usefully used for preventing or treating myositis.

公开(公告)号：US11369718B1

公开(公告)日：2022-06-28

申请号：US16548149

申请日：2019-08-22

申请人： Ariasa LLC

发明人： Alissa Davis Pace

IPC分类号： A61K35/50 ,  A61L27/38 ,  A61L27/36 ,  A61K9/00

摘要： The present technology relates to a method of augmenting soft facial tissue in a human subject using a liquid suspension including amnion allograft. Analysis of the changes to midface volume, specifically the Ogee curve, observed in the chronological progression of photographs illustrates aesthetic improvements in both Platelet Rich Plasma (PRP) and amnion allograft treatment groups, with changes in the facial grading scale. Less patient downtime and slightly more rapid improvements were noted in the amnion group in comparison to PRP treatment participants. As a result, the amnion allograft provides advantages over the PRP procedure.

公开(公告)号：US20220160787A1

公开(公告)日：2022-05-26

申请号：US17439671

申请日：2020-03-16

申请人： Celularity Inc.

发明人： QIAN YE ,  Joseph GLEASON ,  Lin KANG ,  Robert J. HARIRI ,  Shuyang HE ,  Xiaokui ZHANG ,  Valentina ROUSSEVA

IPC分类号： A61K35/50

摘要： The present invention provides an isolated non-human placenta derived stem cell, wherein the stem cell expresses CD90 or wherein the stem cell expresses CD29. The present invention also provides a composition comprising an isolated non-human placenta derived stem cell of the invention or a population of isolated non-human placenta derived stem cells of the invention, and a carrier. The present invention also provides a composition of the invention for use in the manufacture of a medicament to reduce the incidence of rejection in a patient receiving a xenotransplant form a non-human donor. The present invention provides a method of treating a subject receiving a xenotransplant or xenotransfusion comprising the step of administering to the patient an effective amount of a non-human placenta derived stem cells.

公开(公告)号：US11324780B2

公开(公告)日：2022-05-10

申请号：US16175042

申请日：2018-10-30

申请人： Michael P. Zahalsky

发明人： Michael P. Zahalsky

IPC分类号： A61K38/18 ,  A61K35/48 ,  A61L27/38 ,  A61L27/54 ,  A61K9/00 ,  A61K38/24 ,  A61K38/27 ,  A61K35/50 ,  A61K45/06 ,  C12N5/00 ,  A61K38/09 ,  A61K35/16 ,  A61K35/545 ,  A61K31/568 ,  A61K47/42 ,  A61L27/58 ,  C12N5/071 ,  A61L27/36 ,  A61K35/28 ,  A61K35/35 ,  A61L27/22 ,  A61L27/24 ,  C12N5/0775

摘要： A composition for treating a patient with a tissue disease or malformity has a composition containing amniotic fluid. The amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source. A method of treating a patient with a tissue disease or malformity comprises the steps of: identifying the tissue region to be treated and selecting a location to apply either topically or by injection or inhalation a composition containing amniotic fluid; selecting the composition containing amniotic fluid wherein the amniotic fluid has a quantity of gender specific amniotic fluid based on a gender of a fetal source allowing more specific targeted growth factors to be used for specific disease processes; and applying or injecting the composition at or into the selected location.